EligibleTrials

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Recruiting · NCT07404865 · Interventional (participants receive a specific treatment) · Lead sponsor: Vor Biopharma

View the official record on ClinicalTrials.gov →
Rheumatoid arthritis

Interventions studied

PlaceboTelitacicept

What this trial is about

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)

Who can take part

Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

43 locations listed across 15 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.